Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) released its earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01), FiscalAI reports. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.23 million.
Jupiter Neurosciences Price Performance
Shares of NASDAQ JUNS traded down $0.01 during mid-day trading on Friday, hitting $0.34. The company had a trading volume of 40,053 shares, compared to its average volume of 88,968. The business’s 50-day simple moving average is $0.38 and its 200-day simple moving average is $0.78. Jupiter Neurosciences has a 12 month low of $0.31 and a 12 month high of $3.33. The firm has a market cap of $12.26 million, a P/E ratio of -1.25 and a beta of 2.16.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Jupiter Neurosciences stock. Geode Capital Management LLC boosted its holdings in shares of Jupiter Neurosciences, Inc. (NASDAQ:JUNS – Free Report) by 27.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 132,641 shares of the company’s stock after purchasing an additional 28,826 shares during the period. Geode Capital Management LLC owned about 0.39% of Jupiter Neurosciences worth $135,000 as of its most recent SEC filing.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on JUNS
About Jupiter Neurosciences
Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.
Read More
- Five stocks we like better than Jupiter Neurosciences
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
